We describe the molecular cloning and characterization of a novel myeloid inhibitory siglec, MIS, that belongs to the family of sialic acid-binding immunoglobulin-like lectins. A full length MIS cDNA was obtained from murine bone marrow cells. MIS is predicted to contain an extracellular region comprising three immunoglobulin-like domains (V-set amino-terminal domain followed by two C-set domains), a transmembrane domain and a cytoplasmic tail with two immunoreceptor tyrosine-based inhibitory motif (ITIM) -like sequences. The closest relative of MIS in the siglec family is human siglec8. Extracellular regions of these two siglecs share 47 % identity at the amino acid level. Southern blot analysis suggests the presence of one MIS gene. MIS is expressed in the spleen, liver, heart, kidney, lung and testis tissues. Several isoforms of MIS protein exist due to the alternative splicing. In a human pro-monocyte cell line, MIS was able to bind SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2. This binding was mediated by the membrane proximal ITIM of MIS. Moreover, MIS exerted an inhibitory effect on FcγRI receptor-induced calcium mobilization. These data suggest that MIS can play an inhibitory role through its ITIM sequences.
INTRODUCTION
Leukocyte activation is controlled by a dynamic balance between stimulatory and inhibitory signals through activating and inhibitory receptors, respectively. Engagement of the B and T cell antigen receptors, or Fc receptors on specific cells activate a cascade of biochemical events required for cellular activation. However, the termination of such activation signals also represents a critical component of the natural immune response. Deficiency in inhibitory pathways results in profound immune defects characterized by both decreased activation thresholds and hyperresponsive phenotypes which often leads to autoimmunity and inflammation (1) (2) (3) (4) . In contrast, prevalence in signaling through an inhibitory receptor can result in abrogation of signal transduction and cell unresponsiveness (5) . Inhibitory receptors belong to either of two structural types, the immunoglobulin superfamily with type I membrane orientation or the C-type lectin superfamily with type II membrane orientation (reviewed in (6) . Some inhibitory receptors are ubiquitously expressed (7) , while others display a more restricted pattern of expression (8) (9) (10) (11) . Most inhibitory receptors contain one or more characteristic sequences (V/IxYxxL/V) in the cytoplasmic domain termed an Immunoreceptor Tyrosine-based Inhibitory 5 other family members remains unknown, the presence of ITIM sequences in the cytoplasmic tails of some of human siglecs renders them potential inhibitory receptors. Recently, human CD33 has been characterized as an inhibitory receptor by virtue of its ability to bind tyrosine phosphatases SHP-1 and SHP-2 (30, 31).
Although nine human siglec proteins have been discovered, the mouse siglec family has fewer members to date: sialoadhesin, MAG, SMP, CD22 and CD33. Structurally, sialoadhesin, MAG, SMP and CD22 are very similar in mouse and human. In contrast, human and mouse CD33, although somewhat similar in their extracellular domains, are strikingly different in their transmembrane and cytoplasmic regions. Human CD33 contains two ITIM sequences in the cytoplasmic tail whereas mouse CD33 does not. Recent characterization of several ITIMcontaining human siglecs implies that there must be murine ITIM-containing siglecs. Here we describe the molecular cloning and characterization of a novel murine ITIM-containing myeloid 7 Biomedical,San Diego, CA), cross-linking goat anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories, Inc.,West Grove, PA), horseradish peroxidase-conjugated secondary antibodies (Cappel Organon Teknika Corp.,West Chester, PA). Rabbit anti-SHP-1 antiserum was previously described (32).
RT-PCR: Total RNA was isolated from 1x10 7 mouse bone marrow cells, peritoneal macrophages, or various murine cell lines using RNAzol TM (Tel-Test, Inc, Friendswood, TX) according to manufacturer's instructions. 
RESULTS
Molecular cloning of MIS. Considering the sequence similarity between the extracellular domains of mouse and human CD33 and assuming at least partial similarity between the transmembrane regions of hCD33 and a hypothetical mouse inhibitory receptor, we performed a search within a mouse EST-database using the human CD33 transmembrane amino acid sequence in the query. The search resulted in the identification of one murine cDNA clone with 39 % sequence identity to the transmembrane region of hCD33 ( Fig.1 A) . Moreover, there were two ITIMs in the sequence of the mouse clone similar to those of hCD33. The cDNA encoded for the transmembrane and cytoplasmic regions of the protein, and also contained a portion of the 3′ untranslated region. RT-PCR was used to obtain a full length cDNA from murine bone marrow cells. The design of the forward primer (mCD33.1, table 1) was based upon highly homologous stretches of cDNA within the first Ig-like domain in mouse and human CD33. The reverse primer (M1, table 1) was based upon the sequence from the EST clone. A 1.4 kb PCR product was obtained and sequenced. To retrieve the 5′ untranslated region and leader peptide, a 5′ RACE strategy was employed using M1 primer for the first strand cDNA synthesis followed by sequential two rounds of PCR amplification with a universal abridged primer and a set of 12 nested primers, M2 and M3 (Table 1) . To obtain the 3′-end, 3′-RACE was performed using oligo-dT primer for the first strand synthesis and M4 (Table 1) and universal primer for the PCRamplification. In an independent experiment, the full length cDNA was amplified from total RNA isolated from mouse bone marrow cells using M5 and M6 primers deduced from the 5′-RACE and 3′-RACE sequences (Table 1 ).
Sequence analysis of the full length cDNA revealed that the protein had an extracellular domain of 331 residues, a hydrophobic transmembrane domain of 27 residues and a cytoplasmic tail of 93 amino acid residues ( Fig. 1 B .) The sequence begins with a putative hydrophobic signal peptide. The extracellular portion of the molecule contains three Ig-like domains consisting of an N-terminal V-set domain followed by two C2-set domains. In addition, there are ten potential N-glycosylation sites (Asn-X-Ser/Thr) in the extracellular region of the protein.
The cytoplasmic tail contains two potential ITIM sequences. Considering (i) the myeloid cellrestricted pattern of expression of the newly isolated protein (see below), (ii) the similarity of its extracellular domain to the extracellular domains of siglec family members, and (iii) the presence of ITIM-like tyrosine-based signaling motifs, this protein was named MIS, a myeloid inhibitory siglec.
Phylogenetic analysis of the siglec revealed that MIS, siglec8, and siglec7 cluster together, with MIS being mostly closely related to human siglec8. The similarity between MIS protein and other family members ranges from 31% with mCD33 to 47% with human siglec8.
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Amino acid sequence alignment of MIS and three other siglecs, human siglecs 3, and 8 and murine CD33 is shown on Figure 2A . Although human siglec 8 is the closest relative of MIS and shares 57% identity with MIS in the extracellular portion of the molecule, their cytoplasmic tails are quite different. There are no ITIM sequences in the siglec8 cytoplasmic region whereas MIS possess two ITIM-like sequences. To this end, the cytoplasmic tail of MIS is more similar to those of the inhibitory human siglecs, siglec3, -5, -6, and -7 (33%, 29%, 29%, and 33% identity, respectively) ( Fig. 2B) . Thus, these data indicate that MIS belongs to the siglec family and represents a potential inhibitory receptor.
A single MIS gene. To determine whether MIS belongs to a family of closely related genes or represents a single MIS gene, genomic DNA from C57BL/6 mouse was digested with a panel of restriction enzymes and subjected to Southern blot analysis. The probe employed represented an exon corresponding to the first V-SET immunoglobulin-like domain of MIS.
Only one band was observed for each enzyme digestion (Fig. 3) suggesting the presence of only one MIS gene in the mouse genome.
Tissue and cell-restricted expression of MIS. To determine the expression pattern of MIS in adult mouse tissues, Northern blot analysis was performed using the full length MIS cDNA as a probe. As shown on Figure 4A , four mRNA species of approximately 1.6, 1.8, 2.2 and 3.0 kb were detected in different tissues. A transcript of 2.2 kb was expressed (in descending order) in spleen, liver, heart, kidney, and lung (in the latter two tissues this transcript could only be detected after prolonged exposure). In addition to the 2.2 kb transcript, two smaller transcripts 14 were detected in these tissues. The 1.8 kb transcript was expressed in liver and kidney, whereas 1.6 kb transcript was expressed in the spleen and heart. When Northern blot analysis was performed using probes corresponding to the first and third MIS exons that code for the first and third Ig-like domains, respectively, only a 2.2 kb band was observed. Conversely, analysis with a probe corresponding to a cytoplasmic exon revealed multiple bands (data not shown). These data together with results of Southern blot analysis, indicate that there are several MIS variants due to alternative splicing of a single MIS gene. One transcript of 3.0 kb was observed in testis.
The MIS message could not be detected in murine brain and skeletal muscle.
To determine the pattern of cell expression of MIS, a RT PCR approach was utilized.
cDNA was generated from different mouse cell lines, primary bone marrow cells and peritoneal macrophages and the expression of MIS, mCD33 and β-actin was analyzed using gene-specific sets of primers (Fig. 4 B) . (Fig. 4 B, bottom panel) . Hence, the expression of MIS is restricted to cells of myeloid origin.
MIS exists as various isoforms. Alternative mRNA splicing is a common feature among Ig superfamily genes. Since Northern blot analysis of MIS suggested the existence of multiple mRNAs, we next examined the possibility that multiple isoforms of MIS did, indeed, exist.
Mouse total RNA from bone marrow cells was reverse transcribed using the MIS-specific primer, M1, and then, three different sets of primers corresponding to either the first Ig-like domain (M7 and M8), the first and the second Ig-like domains (M7 and M9), or to all three Iglike domains of the molecule (M7 and M10) were used to PCR-amplify cDNA fragments (Fig.   5A ). Amplification with the former two sets of primers each gave rise to a single products of the expected size. However, the third set of primers (M7+M10) yielded two products, one of the predicted size (the higher band on the gel) and a second which was 0.28 kb smaller (Fig. 5B) . Although formally MIS has not been shown to bind sialic acid residues, the inclusion of this protein in the siglec family is justified by the structure of its extracellular region (characteristic amino-terminal V-set domain followed by C-set domains) and the fact that the amino acid residues involved in ligand binding in the other siglecs (24) Human CD33 has been characterized as an inhibitory receptor on myeloid cells based upon its ability to bind inhibitory phosphatases, to inhibit signaling initiated from an activating receptor and to repress dendritic cell development (31, 30, 46) . The other siglec family member that binds SHP-1, p75/AIRM1, has been shown to inhibit the proliferation of normal or leukemic myeloid cells (47) . Similarly, an inhibitory effect of MIS on Ca 2+ mobilization may be due to the recruitment of SHP-1 and SHP-2 to the activating complex.
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The similar structure of ITIM containing cytoplasmic tails of different siglecs dictates the similarity in their inhibitory function. The specificity of siglecs function may be determined either by their unique extracellular regions and/or by their specific expression patterns. Our data indicates that at least two MIS isoforms with either three or two extracellular Ig-like domains exist. In the KIR family, the splicing of one or more Ig-like domains may result in altered ligand recognition (48). In the Siglec family, the amino-terminal V-set domain is responsible for ligand binding (24) , therefore the loss of the second Ig-like domain in a smaller MIS isoform most likely will not affect its ligand binding ability. Sialylation of sialoadhesin and CD22 has been found to regulate their ligand binding activity (49, 50) . In smaller MIS isoform, the splicing out of the second Ig-like domain which contains the majority of N-glycosylation sites may result in a lower overall oligosaccharide content, and thus, in decreased levels of sialylation of the molecule. Therefore, the the ligand binding of MIS isoforms may be differently regulated. As far as the expression pattern is concerned, the early onset of MIS expression in bone marrow cells suggests the possibility that it may be involved in the regulation of monocyte development. Murine β-actin primers: Sense 5′-GCTGTATTCCCCTCCATCGTG-3′ Antisense 5′-CACGGTTGGCCTTAGGGTTCAG-3′ * -all mCD33 primers correspond to mCD33A isoform. (7), , NK cells KY-1 (9), KY-2 (10), mastocytoma P815 (11), and a mock reaction (12). cDNA was reverse transcribed using oligo dT primer and amplified using gene-specific sets of primers, mCD33.2 and mCD33.3 for mCD33 and M4 and M6 for MIS. by guest on 
